About Oralight

Every innovation in healthcare begins with a problem that refuses to be solved the old way. For both adult and pediatric patients undergoing cancer treatment experiencing Oral Mucositis—the burden is real, painful, and often overlooked. We believe there is a better way.

Our company was founded by a multidisciplinary team who came together to rethink how Oral Mucositis is treated, using technology to deliver a therapy with consistency, accuracy, and outcomes clinicians can trust. Such precision medicine should not be optional—it should be the standard.

Our first innovation, an automated Photobiomodulation (PBM) system, redefines how light-based therapy is delivered. By removing variability and human error, we’ve created a platform that is personalized and enables reliable, repeatable, and highly effective treatment—setting a new benchmark for patient care.

But we’re just getting started. We are building a next generation combination therapy that integrates advanced antimicrobial technology with PBM, aiming to transform how Oral Mucositis is treated and delivered. Working alongside a leading cancer center, we are translating science into a real-world clinical workflow that improve lives.

We are at the forefront of addressing mucosal complications that no longer limit recovery, quality of life, or outcomes. Through innovation, collaboration, and focus on patients, we are redefining what’s possible in OM supportive care.